2013
DOI: 10.1016/j.ejmech.2013.02.012
|View full text |Cite
|
Sign up to set email alerts
|

Practical synthesis of a chromene analog for use as a retinoic acid receptor alpha antagonist lead compound

Abstract: Retinoic acid receptor alpha (RARα) selective compounds may guide the design of drugs that can be used in conjunction with hormonal adjuvant therapy in the treatment of breast cancer. Herein we report a modified synthesis of a known RARα antagonist, 2-fluoro-4-[[[8-bromo-2,2-dimethyl-4-(4-methylphenyl)chroman-6-yl]carbonyl]amino]benzoic acid and a synthesis of its unknown, desfluoro analog, 4-[[[8-bromo-2,2-dimethyl-4-(4-methylphenyl)chroman-6-yl]carbonyl]amino]benzoic acid. The modified route allows for facil… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 11 publications
0
2
0
Order By: Relevance
“…9 The approach to address a specific construction of the A 1 -A ring system of GLY II at the start of the synthesis is depicted in retrosynthetic Scheme 3. On the basis of a literature precedent, 11,12 this involves manipulating 7-hydroxycoumarin to form the target ring system and then takes advantage of the previous model chemistry to produce a keto-aldehyde that is poised for an intramolecular benzoin condensation.…”
Section: ■ Results and Discussionmentioning
confidence: 99%
“…9 The approach to address a specific construction of the A 1 -A ring system of GLY II at the start of the synthesis is depicted in retrosynthetic Scheme 3. On the basis of a literature precedent, 11,12 this involves manipulating 7-hydroxycoumarin to form the target ring system and then takes advantage of the previous model chemistry to produce a keto-aldehyde that is poised for an intramolecular benzoin condensation.…”
Section: ■ Results and Discussionmentioning
confidence: 99%
“…Other authors have described the synthesis of novel monofluoro lead compound 2‐fluoro‐4‐[8‐bromo‐2,2‐dimethyl‐4‐(4‐methylphenyl)‐chromen‐6‐yl]‐4‐aminocarbonylbenzoic acid as selective RARα antagonist. Antagonist effects of this fluoro compound were evaluated on the classical ligand‐sensitive promoter activation by RARα in MCF7 breast cancer cells .…”
Section: Introductionmentioning
confidence: 99%